SOURCE: Regen BioPharma Inc.

April 16, 2015 16:01 ET

Regen BioPharma Recruits Renowned Cancer Stem Cell Experts to Scientific Advisory Board

Company Augments Efforts in Acceleration of Cancer Stem Cell Targeting Therapeutics

SAN DIEGO, CA--(Marketwired - Apr 16, 2015) - Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the recruitment of 3 internationally-renowned cancer stem cell experts to its scientific advisory board. The addition is a result of the company's increasing advances in the development of therapeutics targeting what is believed to be "the root of cancer" which is the cancer stem cell. The following is a description of the new members:

Santosh Kesari, MD, PhD, is Director of the Neuro-Oncology Program, Director of the Neurotoxicity Treatment Center, and Director of the Translational Neuro-Oncology Laboratories at Moores Cancer Center and a Professor of Neurosciences at the UC San Diego School of Medicine.

Rohit Duggal, PhD, has 17 years of professional experience in the drug discovery field having worked at Pfizer as a leader of the cancer stem cell group. He has led development of drugs which entered clinical trials, having experience in translating small molecules into clinical candidates, including development of Filibuvir, for which he was granted the prestigious Pfizer Achievement Award. At Genelux Corp he established the cancer stem cell program, which aimed at utilization of viruses to selectively target these cancer initiating cells.

Boris Minev, MD, is Director of Immunotherapy and Translational Oncology at Genelux Corporation studying the phenotype and characterization of metastasized cancer stem cells in circulation. Dr. Minev previously worked as the Principal Investigator at the Laboratory of Tumor Immunology and Immunotherapy at the Moores UCSD Cancer Center. Dr. Minev has an extensive experience with cancer vaccines, having worked closely on the development of the first tumor vaccine to be approved by a regulatory body (Melacine).

"As the company is advancing development of its NR2F6, NR2F2, and CTCFL programs, which all are aimed at targeting cancer stem cells, we felt it was necessary to create a concentration of expertise on our SAB," said Thomas Ichim, PhD, Chief Scientific Officer of Regen. "Having collaborated and published with our new members of the SAB, I look forward to continuing advancing science and at the same time developing new candidates to tackle the extremely relevant issue of cancer stem cells."

"Given the overwhelming acceptance of our novel therapeutic targets in academic and industry meetings, we felt it necessary to identify and recruit key opinion leaders to properly guide us through development of our product candidates through the process of FDA submission and clinical development," said David Koos, CEO and Chairman of Regen.

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information

    Regen BioPharma Inc.
    David R. Koos, PhD
    Chairman & Chief Executive Officer
    619-702-1404 Phone
    619-330-2328 Fax